We are researching and developing a proprietary nasal delivery system (NDS). SNBL's NDS, the μco™ System, consists of two technologies: a safe and muco-adhesive nasal drug carrier technology (in powder form), and a non-invasive and easy-to-use nasal delivery device.
The system increases the value of small molecules and peptides with benefits such as fast-acting and improved absorption. The μco™ System can also be applied to nasal vaccine development, as a more reliable way to prevent infection.
In addition to out-licensing nasal products developed in-house utilizing the μco™ System, SNBL also applies the μco™ System to new and approved compounds and physiologically active substances owned by pharmaceutical companies and thus out-licences the nasal platform technology itself. For detailed information, please refer to the NDS website.